AstraZeneca PLC (LON:AZN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

AstraZeneca PLC (LON:AZN) has been given a consensus recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is £153.33.

AZN has been the topic of a number of research reports. Shore Capital Group reissued a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. Jefferies Financial Group reissued a “buy” rating and issued a £180 price objective on shares of AstraZeneca in a report on Friday, April 10th. Berenberg Bank increased their price objective on AstraZeneca from £145 to £160 and gave the company a “buy” rating in a report on Tuesday, January 27th. JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Finally, Citigroup increased their price objective on AstraZeneca from £170 to £180 and gave the company a “buy” rating in a report on Friday, April 10th.

AstraZeneca Stock Down 1.2%

Shares of AZN stock opened at £133.38 on Thursday. The stock’s 50-day simple moving average is £144.83 and its 200-day simple moving average is £140.20. The company has a debt-to-equity ratio of 71.66, a quick ratio of 0.59 and a current ratio of 0.91. The firm has a market capitalization of £206.85 billion, a PE ratio of 20.09, a P/E/G ratio of 0.86 and a beta of 0.22. AstraZeneca has a fifty-two week low of GBX 9,932 and a fifty-two week high of £157.32.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.